Company Snapshot
- Ticker
- TECH
- Name
- TECH
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 9124182160.000000
- Volume
- 1,645,035
- Avg Volume (3M)
- 2,141,946
TECH
TECH
Last update recent
58.69
+0.18
(+0.31%)
Market Cap
9124182160.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 1216731000.000000
- EPS
- 0.50
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.55%
- Net Income
- 77979000.000000
- Net Margin
- 6.41%
- Payout Ratio
- 64.31%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 117.01
- Forward P/E
- None
- P/S
- 7.50
- P/B
- 4.64
- Beta
- None
- Debt / Equity
- 0.20
- Current Ratio
- 4.22
- Return on Equity
- 0.04%
- Return on Assets
- 0.03%
Technicals & Returns
- Distance vs 200 DMA
- 6.31%
- 200 DMA
- 55.21
- Distance vs 50 DMA
- -4.03%
- 50 DMA
- 61.16
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers Read more
- Name
- TECH
- Industry
- Biotechnology
- CEO
- Mr. Kim Kelderman
- Employees
- 3,100
- IPO Date
- 1989-02-09
- Phone
- 612 379 8854
- Address
- None
- Website
- https://www.bio-techne.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Last Payout
2024-08-19 • $0.08
Latest News
Curated headlines from premium sources.
Bamco Inc. NY Has $143.81 Million Stake in Bio-Techne Corp $TECH
Bamco Inc. NY trimmed its position in Bio-Techne Corp (NASDAQ: TECH) by 14.7% in the second quarter, according to its most recent Form 13F filing with the Secu…
Cerity Partners LLC Boosts Stake in Bio-Techne Corp $TECH
Cerity Partners LLC raised its position in shares of Bio-Techne Corp (NASDAQ: TECH) by 20.3% in the undefined quarter, according to its most recent 13F filing …
Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced a strategic
Bio-Techne Corp $TECH Position Reduced by Brown Advisory Inc.
Brown Advisory Inc. reduced its position in Bio-Techne Corp (NASDAQ: TECH) by 7.2% during the undefined quarter, according to the company in its most recent di…
Bio-Techne Corporation (TECH) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Bio-Techne Corporation (TECH) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript
Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript